Immune Thrombocytopenic Purpura

• Antiplatelet Autoantibodies and Immune Complex Formation: The pathologic cornerstone involves production of IgG autoantibodies (and less commonly IgM or IgA) directed against platelet surface glycoproteins, predominantly GPIIb/IIIa and GPIb/IX complexes. These antibodies form immune complexes that deposit on platelet surfaces, opsonizing platelets for recognition by Fc receptors on macrophages and monocytes within the reticuloendothelial system (particularly splenic macrophages). This antibody-dependent cellular cytotoxicity (ADCC) leads to complement-independent platelet phagocytosis and destruction, producing the characteristic acute thrombocytopenia. The complement cascade may also be activated through classical pathway mechanisms, generating C3b and C4b deposition that enhances Fc receptor-mediated destruction.

• Megakaryocyte Dysfunction and Central Destruction: Beyond peripheral platelet destruction, emerging evidence emphasizes direct immune attack on megakaryocytes within bone marrow, involving both antibody-mediated and T cell-mediated mechanisms. Autoreactive CD8+ cytotoxic T lymphocytes directly target and lyse megakaryocytes expressing platelet glycoprotein epitopes, while Th1 and Th17 differentiation promotes inflammatory cytokine production (IFN-γ, TNF-α, IL-17). This central destruction impairs megakaryocyte maturation, reduces platelet production, and—critically—prevents appropriate compensatory megakaryopoiesis despite severe thrombocytopenia. Bone marrow examination may reveal normal or increased megakaryocytes despite peripheral thrombocytopenia, reflecting this dissociation between production and destruction.

• T Cell Dysregulation and Loss of Immune Tolerance: The fundamental immunologic defect in ITP reflects disturbed T regulatory cell (Treg) function with quantitative and qualitative reductions in CD4+CD25+Foxp3+ Tregs. This loss of immune tolerance permits expansion of autoreactive B cell clones producing anti-platelet antibodies and autoreactive T cell populations targeting megakaryocyte and platelet antigens. Impaired Foxp3 expression and reduced IL-10 and TGF-β production contribute to unchecked Th1/Th17 differentiation. Additionally, abnormal B cell tolerance checkpoints, reduced marginal zone B cells, and altered dendritic cell function combine to sustain the autoimmune response.

• Complement Activation and Thromboinflammation: Beyond ADCC, complement activation via C3a and C5a generation creates a thromboinflammatory state with platelet activation, microparticle release, and tissue factor expression. C5a-mediated recruitment of neutrophils and monocytes amplifies local inflammation and platelet destruction. Some ITP sera contain IgM antibodies with superior complement-fixing capacity, potentially explaining more severe thrombocytopenia in certain patients.

• Genetic Susceptibility and Environmental Triggers: Twin studies and familial ITP cases indicate heritable predisposition, with associations to HLA alleles (particularly HLA-DRB1 and HLA-DQB1). PTPN22 polymorphisms affecting T cell receptor signaling, FAS and FASL variants impairing apoptotic regulation, and BANK1 variants modulating B cell signaling contribute to disease susceptibility. Environmental triggers—including infections (H. pylori, CMV, EBV, parvovirus B19, HIV, HCV), medications (sulfonamides, NSAIDs, heparin), and molecular mimicry from cross-reactive antigens—may precipitate disease onset in genetically predisposed individuals.

• Platelet Kinetics and the Platelet Lifespan Paradox: Normal platelet survival averages 7-10 days; in ITP, autoantibody binding accelerates platelet clearance to 1-3 days despite apparently normal megakaryocyte numbers. The bone marrow cannot compensate adequately even with 5-10 fold increases in megakaryopoiesis, producing the characteristic finding of thrombocytopenia with normal-to-increased megakaryocytes on bone marrow examination. Indium-labeled platelet survival studies can document shortened survival and preferential splenic sequestration in classical ITP.

• Idiopathic autoimmune destruction in genetically predisposed individuals; no specific environmental trigger identified in most cases, though infection-precipitated ITP may occur in previously healthy patients

• HIV infection represents a major secondary cause, affecting 3-5% of HIV+ patients; thrombocytopenia results from HIV-induced B cell activation, direct megakaryocyte infection, and immune complex deposition; severity correlates inversely with CD4 count
• Hepatitis C virus (HCV) infection, particularly in patients with HCV-associated cryoglobulinemia; immune complex-mediated platelet destruction predominates; HCV clearance with direct-acting antivirals often resolves ITP
• Systemic lupus erythematosus (SLE) and other autoimmune diseases account for 5-10% of secondary ITP; lupus anticoagulant and anti-phospholipid antibodies frequently coexist; ITP may precede other lupus manifestations
• Antiphospholipid syndrome (APS) presents with thrombocytopenia and thrombotic complications; anti-β2-glycoprotein-I and anticardiolipin antibodies mediate platelet destruction
• Lymphoproliferative disorders, particularly chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma; autoimmune thrombocytopenia occurs in 2-10% of CLL patients through mechanisms including anti-platelet antibody production by malignant B cells
• Solid malignancies (ovarian, gastric, lung) through paraneoplastic mechanisms and immune complex deposition
• Post-vaccination ITP (particularly following measles-containing vaccines, varicella, and hepatitis A vaccines); typically develops within 4 weeks of vaccination; usually self-limited
• Drug-induced ITP: certain drugs act as haptens (quinine, sulfonamides, NSAIDs, trimethoprim-sulfamethoxazole) or induce anti-platelet antibodies directly; heparin-induced thrombocytopenia (HIT) represents a distinct immune-mediated thrombocytopenia with thrombotic complications
• H. pylori infection in seropositive patients; eradication therapy results in platelet count recovery in 50-70% of infected patients, particularly in Japan and Southern Europe where prevalence correlates with geographic ITP incidence
• Chronic infections including tuberculosis, syphilis, and endemic fungi
• Pregnancy-associated ITP affects 0.1-0.2% of pregnancies; gestational thrombocytopenia (platelet count 130,000-150,000/μL) must be distinguished from true ITP; true ITP carries fetal risk through transplacental IgG antibody transfer

• Petechiae and Purpura: The hallmark manifestation results from platelet counts <30,000/μL with spontaneous capillary rupture; petechiae appear as pinpoint erythematous macules 1-3 mm diameter that do not blanch with pressure (distinguishing them from blanchable erythema). Purpura represents larger coalescent areas (>3 mm) indicating more confluent hemorrhage. Lesions typically appear first on lower extremities and areas of pressure/trauma due to hydrostatic pressure gradient and mechanical stress. Absence of petechiae despite platelet count <20,000/μL suggests protective effect of concurrent steroid therapy or implies alternative diagnosis.

• Mucosal Bleeding: Gingival bleeding, epistaxis, and menorrhagia represent early manifestations even with moderate thrombocytopenia (30,000-50,000/μL) due to the high shear stress environment and endothelial disruption in mucosal vascular beds. Menorrhagia (often the presenting symptom in women) may be severe, leading to iron deficiency anemia and iron overload with chronic transfusions. Oral bleeding manifests as blood-filled blisters or hemorrhagic bullae in severe cases.

• Gastrointestinal and Genitourinary Hemorrhage: GI bleeding presents with melena, hematochezia, or positive fecal occult blood and becomes increasingly likely with platelet counts <10,000/μL, though significant GI bleeding can occur at higher counts if additional hemostatic defects coexist. Hematuria may be spontaneous or provoked by minor urological procedures. The distinction between ITP-related and concurrent organic GI pathology (peptic ulcer, angiodysplasia) requires judicious upper and lower endoscopy evaluation.

• Intracranial Hemorrhage (ICH): The most feared complication, occurring in 0.5-5% of ITP cases, typically when platelet count falls <10,000/μL or with rapid acute thrombocytopenia. Presents with severe headache, focal neurologic deficits, altered consciousness, or seizures. Subdural hematomas and intracerebral bleeds predominate; mortality approaches 25% even with aggressive treatment. ICH risk increases substantially with platelet counts <5,000/μL and concurrent anticoagulation or coagulopathy.

• Constitutional Symptoms: In acute ITP, fever, malaise, and myalgias may accompany or precede thrombocytopenia, reflecting the underlying immune activation. Chronic ITP patients often report fatigue attributable to anemia from chronic bleeding, iron deficiency, or comorbid autoimmune conditions.

• Physical Examination Findings: Splenomegaly should NOT be present in primary ITP; its detection mandates investigation for secondary causes including lymphoproliferative malignancy, infection, or cirrhosis. Hepatomegaly similarly suggests secondary ITP. Petechiae characteristically spare mucosal surfaces early (unlike viral exanthems). Fundoscopic examination in severe thrombocytopenia may reveal retinal hemorrhages or cotton-wool spots indicating severe thrombocytopenic coagulopathy.

• Acute vs Chronic Presentations: Acute ITP (onset over days to weeks) occurs predominantly in children and young adults, often following viral infection, and frequently demonstrates spontaneous remission (>80% in children). Classic presentation includes sudden-onset petechiae and severe thrombocytopenia; hemorrhagic manifestations may be dramatic. Chronic ITP (duration >3 months) predominates in adults and follows an insidious course with gradual platelet decline; patients often remain asymptomatic despite platelet counts of 20,000-30,000/μL due to adaptation and compensatory mechanisms.

• Asymptomatic Thrombocytopenia: Paradoxically, many patients with chronic ITP and platelet counts of 30,000-50,000/μL remain entirely asymptomatic without spontaneous bleeding, representing a major challenge in determining treatment necessity. The absence of bleeding symptoms in the setting of severe thrombocytopenia should not be interpreted as disease inactivity but rather reflects individual variation in hemostatic reserve.

• Complete Blood Count with Peripheral Blood Smear: Establishes thrombocytopenia (platelet count <150,000/μL; ITP diagnosis typically requires count <100,000/μL at some point) and excludes other cytopenias that would suggest alternative diagnosis (e.g., Evans syndrome with concurrent hemolytic anemia). The smear reveals normal platelet morphology and size; abnormalities suggest alternative diagnosis (schistocytes in TTP/HUS, blast cells in leukemia, immature cells in myelodysplasia). Giant platelets warrant investigation for MYH9-related disorders or other congenital macrothrombocytopenias. Manual platelet counting may be necessary if automated counters fail due to extreme thrombocytopenia.

• Bone Marrow Examination: NOT routinely required for diagnosis in young patients with characteristic presentation (isolated thrombocytopenia, positive response to corticosteroids). However, indicated if: (1) age >60 years at presentation to exclude myelodysplasia or hematologic malignancy, (2) concurrent anemia or leukopenia suggesting alternative diagnosis, (3) failure to respond to standard ITP therapy (raising concern for undiagnosed myelodysplasia or malignancy), or (4) atypical clinical features. Bone marrow typically shows normal or increased megakaryocytes (distinguishing ITP from bone marrow failure), normal erythropoiesis, and normal myelopoiesis. This finding—thrombocytopenia with increased bone marrow megakaryocytes—represents the classic diagnostic pattern.

• Platelet-Associated Immunoglobulin (PAIg): Detects IgG, IgM, or IgA bound to platelet surface or in platelet cytoplasm using flow cytometry or ELISA-based techniques. Positive PAIg (elevated above normal controls) has 80-85% sensitivity and 90-95% specificity for immune-mediated thrombocytopenia, making it the most specific available laboratory test. However, PAIg positivity alone is insufficient for ITP diagnosis as it occurs in other immune cytopenias (autoimmune hemolytic anemia, Evans syndrome) and transfused patients. Negative PAIg does not exclude ITP as 10-15% of ITP patients demonstrate negative results. Thus, PAIg serves as supporting evidence rather than diagnostic criterion.

• Antiplatelet Antibody Specificity Testing: Specialized testing identifies autoantibodies directed against specific glycoproteins (GPIIb/IIIa, GPIb/IX, GPVI) using monoclonal antibody immobilization of platelet antigen (MAIPA) or other techniques. More commonly used in research settings; limited clinical utility for routine diagnosis but may predict treatment response (anti-GPIb antibodies associated with steroid-refractory disease).

• Infectious Serology: Required in all ITP patients to identify secondary causes: HIV antibody or antigen test (4th generation test), hepatitis C antibody with reflex to HCV RNA if positive, hepatitis B surface antigen, and H. pylori serology particularly in endemic regions or if considering eradication therapy. Rapid plasma reagin (RPR) screens for syphilis-associated thrombocytopenia. Additional testing based on clinical suspicion (EBV, CMV titers) in younger patients or those with constitutional symptoms.

• Autoimmune Serology: Antinuclear antibody (ANA), anti-dsDNA, and complement levels screen for SLE; antiphospholipid antibodies (anticardiolipin, anti-β2-glycoprotein-I, lupus anticoagulant) identify APS with thrombotic risk. These tests identify secondary ITP subsets with implications for treatment and management.

• Imaging Studies: Not routinely required for diagnosis; however, abdominal ultrasound or CT may assess spleen size if clinical examination suggests hepatosplenomegaly (which would indicate secondary ITP or alternative diagnosis). CT chest/abdomen indicated if lymphoproliferative malignancy suspected. Brain imaging (CT or MRI) mandatory in patients with neur

Emergency (life-threatening bleeding — ICH, GI hemorrhage)

• Combination therapy: IV corticosteroid (methylprednisolone) plus IVIG plus platelet transfusion given simultaneously. Unlike TTP or HIT, platelet transfusion is not contraindicated in ITP; transfused platelets are consumed rapidly but can transiently plug bleeding sites, and IVIG blockade of splenic Fc receptors prolongs their survival.
• Adjuncts: antifibrinolytics (tranexamic acid) for mucosal bleeding; hold aspirin, NSAIDs, and anticoagulants; consider emergency splenectomy or vinca alkaloids only if refractory.

Initial (first-line) therapy

• Observation: ASH suggests no treatment for adults who are asymptomatic with platelets ≥30,000/μL, and for children with no or minor bleeding regardless of count, since most pediatric ITP remits spontaneously.
• Corticosteroids: prednisone 1 mg/kg/day or dexamethasone 40 mg daily × 4 days. ASH favors a short course (≤6 weeks including taper) — steroids reduce Fc receptor–mediated clearance and autoantibody production, but prolonged use is explicitly discouraged.
• IVIG (or anti-D in Rh(D)-positive, non-splenectomized patients) when a rise in count is needed within 24–48 hours (surgery, active bleeding, pregnancy at delivery).

Second-line options (ASH treats these as roughly equivalent, chosen by patient preference and duration of disease)

• TPO receptor agonists: eltrombopag, romiplostim, avatrombopag — stimulate megakaryopoiesis, overcoming the impaired platelet production described above.
• Rituximab: anti-CD20 depletion of autoantibody-producing B cells; screen for hepatitis B before use.
• Fostamatinib: SYK inhibitor blocking Fc receptor signal transduction in macrophages.
• Splenectomy: the most definitive therapy (durable remission in a majority), but ASH recommends deferring it at least 12 months from diagnosis to allow spontaneous or drug-induced remission; give pneumococcal, meningococcal, and H. influenzae type b vaccines beforehand per ACIP.

Disease-related

• Intracranial hemorrhage — the emergency. Occurs mainly with counts <10,000/μL or abrupt severe drops; signaled by headache, vomiting, focal deficit, seizure, or altered mental status. Any such symptom in a thrombocytopenic patient mandates immediate non-contrast head CT and simultaneous steroid + IVIG + platelet transfusion before imaging results if unstable.
• Major GI or genitourinary hemorrhage — melena, hematochezia, or gross hematuria; also an emergency requiring transfusion support.
• Iron deficiency anemia — from chronic menorrhagia or occult GI loss; microcytosis with low ferritin. New anemia should also prompt consideration of Evans syndrome (ITP plus autoimmune hemolytic anemia), signaled by reticulocytosis, high LDH, low haptoglobin, and a positive direct antiglobulin test.
• Chronic/refractory disease — persistent thrombocytopenia beyond 12 months; in adults, failure to respond should re-open the differential (MDS, CLL, drug effect).

Treatment-related

• Corticosteroids: hyperglycemia, hypertension, osteoporosis, avascular necrosis of the femoral head, myopathy, mood disturbance/psychosis, and adrenal suppression with abrupt withdrawal — the reason ASH caps initial courses at ≤6 weeks.
• IVIG: aseptic meningitis (severe headache with sterile CSF pleocytosis), acute kidney injury (osmotic tubular injury, historically sucrose-containing products), volume overload, hemolysis from anti-A/anti-B isoagglutinins in non-group-O recipients, and thrombosis.
• IV anti-D: carries an FDA boxed warning for intravascular hemolysis with DIC and renal failure; signaled by back pain, dark urine, and a falling hemoglobin after infusion.
• Rituximab: hepatitis B reactivation (screen HBsAg and anti-HBc first), hypogammaglobulinemia, infusion reactions, and rare progressive multifocal leukoencephalopathy.
• TPO receptor agonists: thrombosis, hepatotoxicity (particularly eltrombopag), marrow reticulin, and rebound thrombocytopenia on abrupt discontinuation.
• Splenectomy: overwhelming post-splenectomy infection with encapsulated organisms (S. pneumoniae, N. meningitidis, H. influenzae) — a true emergency presenting as fulminant sepsis; also portal/splenic vein thrombosis. Howell-Jolly bodies on smear confirm asplenia.

• The classic triad of the stem: isolated thrombocytopenia, a normal peripheral smear, and no splenomegaly. Any schistocytes, blasts, leukopenia, or a palpable spleen argues against primary ITP.
• Best next step in a well child with petechiae 1–2 weeks after a viral URI and platelets of 15,000/μL and no bleeding: observation. Per ASH 2019, pediatric ITP is managed by bleeding severity, not count, and most remit spontaneously. Reflexively choosing IVIG or steroids is the classic trap.
• Best next step with life-threatening bleeding: steroids plus IVIG plus platelet transfusion together. Remember the contrast — platelet transfusion is withheld in TTP and HIT (fuels microthrombi) but is appropriate in ITP.
• Bone marrow biopsy is not required for a typical presentation. It is reserved for older adults, other cytopenias, or treatment failure. When done, the buzzword is normal-to-increased megakaryocytes — destruction, not production failure. Antiplatelet antibody testing is likewise not required to make the diagnosis.
• The association examiners love: ITP is a diagnosis of exclusion — always test for HIV and HCV (plus H. pylori where relevant). Treating the underlying infection can resolve the thrombocytopenia.
• Pregnancy: maternal IgG crosses the placenta and can cause neonatal thrombocytopenia; check a cord/neonatal platelet count. Mode of delivery is decided by obstetric indications, not platelet count; avoid fetal scalp electrodes and vacuum extraction. Distinguish from benign gestational thrombocytopenia (mild, late, no fetal effect) and from HELLP/preeclampsia.
• Splenectomy is the most durable therapy but should be deferred ~12 months; vaccinate against encapsulated organisms beforehand. Post-splenectomy Howell-Jolly bodies confirm asplenia.
• Drug pitfalls: IV anti-D works only in Rh(D)-positive, non-splenectomized patients and carries a hemolysis boxed warning; screen for hepatitis B before rituximab; withhold aspirin, NSAIDs, and anticoagulants in any bleeding ITP patient.